201 related articles for article (PubMed ID: 16239415)
1. Enteric-coated mycophenolate sodium for transplant immunosuppression.
Ingle GR; Shah T
Am J Health Syst Pharm; 2005 Nov; 62(21):2252-9. PubMed ID: 16239415
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.
Staatz CE; Tett SE
Clin Pharmacokinet; 2007; 46(1):13-58. PubMed ID: 17201457
[TBL] [Abstract][Full Text] [Related]
3. Mycophenolic acid metabolite profile in renal transplant patients receiving enteric-coated mycophenolate sodium or mycophenolate mofetil.
Tedesco-Silva H; Bastien MC; Choi L; Felipe C; Campestrini J; Picard F; Schmouder R
Transplant Proc; 2005 Mar; 37(2):852-5. PubMed ID: 15848554
[TBL] [Abstract][Full Text] [Related]
4. Absorption characteristics of EC-MPS--an enteric-coated formulation of mycophenolic sodium.
Arns W; Gies M; Choi L; Zhu W; Cooper P; Yeh CM; Prasad P; Graf P; Schmouder R
Int J Clin Pharmacol Ther; 2006 Aug; 44(8):375-85. PubMed ID: 16961168
[TBL] [Abstract][Full Text] [Related]
5. Enteric-coated mycophenolate sodium: tolerability profile compared with mycophenolate mofetil.
Behrend M; Braun F
Drugs; 2005; 65(8):1037-50. PubMed ID: 15907141
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetics of mycophenolate mofetil.
Bullingham RE; Nicholls AJ; Kamm BR
Clin Pharmacokinet; 1998 Jun; 34(6):429-55. PubMed ID: 9646007
[TBL] [Abstract][Full Text] [Related]
7. Enteric-coated mycophenolate sodium: a review of its use in the prevention of renal transplant rejection.
Sanford M; Keating GM
Drugs; 2008; 68(17):2505-33. PubMed ID: 19016576
[TBL] [Abstract][Full Text] [Related]
8. A prospective analysis of the effects of enteric-coated mycophenolate sodium and mycophenolate mofetil co-medicated with a proton pump inhibitor in kidney transplant recipients at a single institute in China.
Xu L; Cai M; Shi BY; Li ZL; Li X; Jin HL
Transplant Proc; 2014 Jun; 46(5):1362-5. PubMed ID: 24935300
[TBL] [Abstract][Full Text] [Related]
9. Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil.
Arns W; Breuer S; Choudhury S; Taccard G; Lee J; Binder V; Roettele J; Schmouder R
Clin Transplant; 2005 Apr; 19(2):199-206. PubMed ID: 15740555
[TBL] [Abstract][Full Text] [Related]
10. Review of the immunosuppressant enteric-coated mycophenolate sodium.
Budde K; Glander P; Diekmann F; Waiser J; Fritsche L; Dragun D; Neumayer HH
Expert Opin Pharmacother; 2004 Jun; 5(6):1333-45. PubMed ID: 15163278
[TBL] [Abstract][Full Text] [Related]
11. The proton pump inhibitor pantoprazole and its interaction with enteric-coated mycophenolate sodium in transplant recipients.
Kofler S; Wolf C; Shvets N; Sisic Z; Müller T; Behr J; Sohn HY; Vogeser M; Shipkova M; Meiser B; Steinbeck G; Reichart B; Kaczmarek I
J Heart Lung Transplant; 2011 May; 30(5):565-71. PubMed ID: 21256049
[TBL] [Abstract][Full Text] [Related]
12. Enteric-coated mycophenolate sodium: safe conversion from mycophenolate mofetil in maintenance renal transplant recipients.
Budde K; Glander P; Diekmann F; Dragun D; Waiser J; Fritsche L; Neumayer HH
Transplant Proc; 2004 Mar; 36(2 Suppl):524S-527S. PubMed ID: 15041401
[TBL] [Abstract][Full Text] [Related]
13. Better mycophenolic acid 12-hour trough level after enteric-coated mycophenolate sodium in patients with gastrointestinal intolerance to mycophenolate mofetil.
Sánchez Fructuoso A; Calvo N; Moreno MA; Giorgi M; Conesa J; Barrientos A
Transplant Proc; 2007 Sep; 39(7):2194-6. PubMed ID: 17889135
[TBL] [Abstract][Full Text] [Related]
14. Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated mycophenolate sodium.
Ortega F; Sánchez-Fructuoso A; Cruzado JM; Gómez-Alamillo JC; Alarcón A; Pallardó L; Morales JM; Oliver J; Guinea G;
Transplantation; 2011 Aug; 92(4):426-32. PubMed ID: 21760569
[TBL] [Abstract][Full Text] [Related]
15. No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study.
Rissling O; Glander P; Hambach P; Mai M; Brakemeier S; Klonower D; Halleck F; Singer E; Schrezenmeier EV; Dürr M; Neumayer HH; Budde K
Br J Clin Pharmacol; 2015 Nov; 80(5):1086-96. PubMed ID: 25913040
[TBL] [Abstract][Full Text] [Related]
16. Enteric-coated mycophenolate sodium.
Gabardi S; Tran JL; Clarkson MR
Ann Pharmacother; 2003 Nov; 37(11):1685-93. PubMed ID: 14565799
[TBL] [Abstract][Full Text] [Related]
17. Superior efficacy of enteric-coated mycophenolate vs mycophenolate mofetil in de novo transplant recipients: pooled analysis.
Salvadori M; Bertoni E; Budde K; Holzer H; Civati G; Lien B; Arns W
Transplant Proc; 2010 May; 42(4):1325-8. PubMed ID: 20534293
[TBL] [Abstract][Full Text] [Related]
18. Enteric-coated mycophenolate sodium: therapeutic equivalence to mycophenolate mofetil in de novo renal transplant patients.
Sollinger H
Transplant Proc; 2004 Mar; 36(2 Suppl):517S-520S. PubMed ID: 15041399
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and variability of mycophenolic acid from enteric-coated mycophenolate sodium compared with mycophenolate mofetil in de novo heart transplant recipients.
Hummel M; Yonan N; Ross H; Miller LW; Sechaud R; Balez S; Koelle EU; Gerosa G;
Clin Transplant; 2007; 21(1):18-23. PubMed ID: 17302587
[TBL] [Abstract][Full Text] [Related]
20. Stable renal transplant recipients can be safely converted from MMF to enteric-coated mycophenolate sodium tablets: Interim results of a multicenter Latin American study.
Abbud-Filho M; Girón F; Hernández E; Juarez F; Liendo C; Novoa P; Toledo M;
Transplant Proc; 2004; 36(6):1647-9. PubMed ID: 15350440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
